Epidemiological analysis of serological markers of hepatitis B in HIV+ patients from Curitiba and metropolitan region

Conclusion: The findings of the present study corroborate the need to investigate systematically the presence of markers for HBV in HIV+ patients from different regions of the country. Introdução: A presença do vírus da hepatite B (HBV) em indivíduos infectados pelo vírus da imunodeficiência humana (HIV) está associada ao significante aumento da morbimortalidade nos pacientes afetados. Objetivo: Estabelecer a prevalência de marcadores sorológicos de HBV e dos fatores epidemiológicos associados em pacientes HIV+ acompanhados pelo Hospital de Clínicas da Universidade Federal do Paraná (HC-UFPR). Métodos: Os dados clinicoepidemiológicos foram coletados por meio de análise retrospectiva dos prontuários e de aplicação de um questionário. Os marcadores anti-HBc total e o antígeno HbsAg foram avaliados pela quimioluminescência por micropartículas. Resultados e discussão: Dos 297 pacientes HIV+, 49,8% apresentaram sorologia positiva somente para anti-HBc e 2,6%, para anti-HBc e HbsAg. A prevalência de marcadores de hepatite B foi significantemente associada à infecção pelo HIV quando comparada com a prevalência observada na população geral da mesma área geográfica (anti-HBc+/HbsAg+: 0,14% vs. 2,6%, odds ratio (OR): 18,82, intervalo de confiança (IC) 95%: ...
Source: Jornal Brasileiro de Patologia e Medicina Laboratorial - Category: Pathology Source Type: research

Related Links:

This study aims to analyze the prevalence and to concentrate on the key risk factors that are responsible for hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) infection in patients on HD visiting two dialysis centers in the city of Quetta in southwestern Pakistan. The overall incidence of HBV was found to be 16.1%, the overall incidence of HCV was found to be 43.2%, and two patients (1.6%) were found to be positive for both HBV and HCV. HIV was not found among patients seen at both hospitals during the study period. The main risk factors for development of a viral infection were the ...
Source: Drug Discoveries and Therapeutics - Category: Drugs & Pharmacology Tags: Drug Discov Ther Source Type: research
Abstract Hexavalent vaccines containing diphtheria, tetanus, pertussis, Haemophilus influenzae type b, poliomyelitis, and hepatitis B virus antigens have the potential to be used for the primary series in India (6, 10, 14 weeks of age) and the toddler booster dose. Three hexavalent vaccines are available in India: DTwP-Hib/HepB-IPV (wP-hexa), DTaP-IPV-HB-PRP~T(2aP-hexa), and DTaP-HBV-IPV/Hib (3aP-hexa). In the three published phase-3 Indian studies, pertussis 'vaccine response' rates 1 month after a 6-10-14-week primary series were 68.4-75.7% for wP-hexa, 93.8-99.3% for 2aP-hexa, and 97.0-100% for 3aP-hexa; seropr...
Source: Indian Pediatrics - Category: Pediatrics Authors: Tags: Indian Pediatr Source Type: research
Condition:   Hepatitis B Vaccination Interventions:   Biological: Subcutaneous fat injection of Recombivax-HB;   Biological: Intramuscular injection of Recombivax-HB Sponsor:   University of Maryland, Baltimore Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Chronic hepatitis B (CHB) is a global health problem caused by human hepatitis B virus (HBV). Current treatment with interferons and nucleos(t)ide analogs (NAs) can cause population tolerance and drug resistance. Therefore, new antiviral drugs, especially those targeting host factors, are urgently needed. Here, we identified Evans blue as a new HBV inhibitor by screening an FDA drug library using Huh7DhNTCP cells and confirmed the antiviral activity in primary human hepatocytes and human sodium taurocholate cotransporting polypeptide (hNTCP)-transfected porcine primary hepatocytes. Our efficacy study showed that Evans blue...
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
We present a narrative review of HCC in Africa, discussing present and future trends. [...] Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.Article in Thieme eJournals: Table of contents  |  Abstract  |  Full text
Source: Seminars in Liver Disease - Category: Gastroenterology Authors: Tags: Review Article Source Type: research
AbstractIn the present work, QSAR (quantitative structure −activity relationship) analysis has been executed for RG7834 analogs. RG7834 is a first-in-class selective and orally available dihydroquinolizinone (DHQ)-based small molecule Hepatitis B virus expression inhibitor. OECD’s guidelines have been followed for developing multiple QSAR models for He patitis B virus expression inhibitory activity of 73 RG7834 analogs. The present multiple QSAR models are not only easily interpretable but possess high external predictive ability, as well. These are effective in the recognition of many privileged and underprivi...
Source: Medicinal Chemistry Research - Category: Chemistry Source Type: research
Conditions:   Hepatitis B, Chronic;   Hepatocellular Carcinoma;   Compensated Cirrhosis Interventions:   Drug: Entecavir;   Drug: Tenofovir Disoproxil Sponsors:   Qing XIe;   Shanghai MedSci Healthcare Co. Ltd Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
AbstractBackground and AimsThe features of non-viral, nonalcohol hepatocellular carcinoma (NBNC-HCC) remain elusive. The aim of this study was to investigate this clinical characteristics and overall survival of NBNC-HCC compared to hepatitis B- (HBV-HCC) and hepatitis C-related (HCV-HCC) HCC.MethodsWe analyzed the etiologies, fibrosis stages, clinical data, and outcomes of newly diagnosed patients with HCC.ResultsA total of 1777 HCC patients were recruited, including 332 patients with NBNC-HCC, 682 patients with HBV-HCC, 680 patients with HCV-HCC, and 83 patients with HBV/HCV HCC. Patients with NBNC-HCC were older (69.9 &...
Source: Digestive Diseases and Sciences - Category: Gastroenterology Source Type: research
Abstract Recent evidence suggests herbal-induced liver injury (HILI) to account for 20% of cases among the U.S. Drug-Induced-Liver-Injury-Network. To define injury patterns of HILI, we reviewed the clinical data of 413 patients exposed to 53 HDS products by considering the evidence for HILI and its grades of severity. Outstandingly, females developed HILI more rapidly (p = 0.018) and the time to recovery was significantly increased (p = 0.0153). > 90% of reported cases were severe and half of HDS products caused acute liver failure (ALF) requiring liver transplantation ...
Source: Archives of Toxicology - Category: Toxicology Authors: Tags: Arch Toxicol Source Type: research
We read with great interest the article, ‘A multi-center study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in the Republic of Korea’ by Kim et al., published in the Journal of Hepatology.1 The authors concluded that the risk of hepatocellular carcinoma (HCC) and death or orthotopic liver transplant w as no different between entecavir (ETV) and tenofovir (TDF) groups. Their findings were not consistent with the results of a study by Choi et al.2
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Letter to the Editor Source Type: research
More News: Chemistry | Epidemiology | Hepatitis | Hepatitis B | Liver | Pathology | Study | Urology & Nephrology